// App-Quantinova.ai

392 : Combined targeting of MET and PI3K improves efficacy in breast cancer models with concurrent MET/PI3K aberrations

Researchers

Presenter

  • Shuying Liu

Principal Investigators

  • Naoto T. Ueno

  • Bailiang Wang

  • Mihai Gagea

  • Prahlad T. Ram

  • Mark Merchant

  • John Mendelsohn

  • Debasish Tripathy

  • Gordon B. Mills

  • Ana M. Gonzalez-Angulo

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • Roche/Genentech, South San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Combined immunodeficiencies

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Solute Carrier Family 25 Member 16

Drug/Treatment

  • Onartuzumab

  • Pictilisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved